 The study will assess canagliflozin JNJ-28431754 in the treatment of patients with type 2 diabetes mellitus T2DM with regard to cardiovascular CV risk for major adverse cardiac events MACE. Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin. 